| Name | Title | Contact Details |
|---|
Myovant Sciences is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for women`s health diseases and other endocrine-related disorders. Myovant`s lead product candidate is relugolix, an oral, once-daily, small molecule that acts as a GnRH receptor antagonist. Myovant is in the process of initiating five international Phase 3 clinical trials for relugolix, two in women with heavy menstrual bleeding associated with uterine fibroids, two in women with endometriosis-associated pain, and one in men with advanced prostate cancer. Myovant is simultaneously developing MVT-602, an analog of kisspeptin, for the treatment of female infertility as part of assisted reproduction. Over time, the company intends to expand its development pipeline to include other potential treatments for women`s health and endocrine-related disorders.
SyntheZyme develops bio-based products and technologies with a unique and competitive cost/performance. We work closely together with our industrial partners for the manufacture and marketing of our bio-based commodity and specialty products for the global market. We seek to complement our core competencies with those of our strategic, industrial partners. The success of our business is based on our capabilities to structure and operate entrepreneurial partnerships. SyntheZyme’s scientists and engineers have a deep knowledge in chemistry, synthetic biology, fermentation engineering and materials science with process know-how
StemoniX microHeart® products in high density plate formats provide researchers with structurally aligned cardiac cells resembling native human heart tissue with accelerated features of cell maturity.
Aragen Biosciences is a Morgan Hill, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Genosco is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.